Form 4 for EDIT Editas Medicine, Inc.
Accepted 2023-05-18 00:00:00 ET · period of report 2023-05-17 · accession 0001415889-23-008293 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-18 | 2023-05-17 | EDIT | Lucera Erick | EVP, CFO | A - Grant | $0.00 | +77.9K | 77.9K | New | $0 |
| D | 2023-05-18 | 2023-05-17 | EDIT | Lucera Erick | EVP, CFO | A - Grant | $0.00 | +155.8K | 155.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-17 | A | A | 77,900 | $0.00 | 77,900 | D | — | — | (F1) The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on May 17, 2024 continuing through May 17, 2027. |
| 2 | Derivative | Stock Option (right to buy) | 2023-05-17 | A | A | 155,800 | $0.00 | 155,800 | D | $9.61 · — to 2033-05-16 | 155,800 Common Stock | (F2) This option was granted on May 17, 2023 and is scheduled to vest over four years, with 25% of the shares to vest on May 17, 2024 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through May 17, 2027. |